Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

Blood(2020)10.1182/blood.2019003988Source: DataRank Database

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML is a research paper published in Blood (2020). On theSindex it has a DataRank of 12.6. It has been cited 659 times, with 200 citing works in its 1-hop citation network.

N/A

12.6DataRank · unranked

Scored on demand from live citation data

Open Access659 citations · 200 citing works in its network

Download PDF

Cite:

Linked data & code

nct ega

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)OA: bronzeTopics (42)Linked Datasets (8)DataCite Reuse (8)IDs (PubMed, PMC)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 8%Citation Network 92%

Base Score Contribution

0.974

From this paper's citation signal

Citation Network Contribution

11.6

From 200 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 200 citers.

The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy
American Journal of Hematology202116 citations6 referencesContributes 0.472
Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
Haematologica202332 citations12 referencesContributes 0.291
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice
American Journal of Hematology202132 citations13 referencesContributes 0.269
Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
Haematologica202249 citations16 referencesContributes 0.245
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
Journal of Clinical Oncology2021272 citations23 referencesContributes 0.244

Authors (29)

Ing Soo Tiong ORCID,Anna Quaglieri ORCID,Sarah MacRaild,Sanam Loghavi ORCID,Fiona C. Brown ORCID

Live enrichment

PubMed:31932844 PMC:PMC7068032

NCI NIH HHS

Grant: P30 CA016672

bronzeLicense: other-oa

publisherhttps://ashpublications.org/blood/article-pdf/135/11/791/1779887/bloodbld2019003988.pdf

publisherhttp://ashpublications.org/blood/article-pdf/135/11/791/1779887/bloodbld2019003988.pdf

repositoryhttps://pure.amsterdamumc.nl/ws/files/136561905/bloodbld2019003988.pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7068032

Fields of Study

Age FactorsAgedAged, 80 and overAllelesAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBridged Bicyclo Compounds, HeterocyclicComputational BiologyDrug Resistance, NeoplasmGene Expression ProfilingHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMutationNucleophosminPrognosisRetreatmentSulfonamidesTreatment FailureTreatment Outcome

MeSH Terms

HumansSulfonamidesAntineoplastic Combined Chemotherapy ProtocolsPrognosisTreatment OutcomeTreatment FailureRetreatmentGene Expression ProfilingComputational BiologyAge FactorsDrug Resistance, NeoplasmMutationAllelesAgedAged, 80 and overMiddle AgedMaleLeukemia, Myeloid, AcuteBiomarkers, TumorBridged Bicyclo Compounds, HeterocyclicNucleophosmin

Additional file 1 of C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription

10.6084/m9.figshare.25397464.v1figshare

Additional file 1 of C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription

10.6084/m9.figshare.25397464figshare

Additional file 2 of Diversifying the anthracycline class of anti-cancer drugs identifies aclarubicin for superior survival of acute myeloid leukemia patients

10.6084/m9.figshare.25963331.v1figshare

Additional file 2 of Diversifying the anthracycline class of anti-cancer drugs identifies aclarubicin for superior survival of acute myeloid leukemia patients

10.6084/m9.figshare.25963331figshare

Additional file 1 of Diversifying the anthracycline class of anti-cancer drugs identifies aclarubicin for superior survival of acute myeloid leukemia patients

10.6084/m9.figshare.25963178.v1figshare

Additional file 1 of Diversifying the anthracycline class of anti-cancer drugs identifies aclarubicin for superior survival of acute myeloid leukemia patients

10.6084/m9.figshare.25963178figshare

Additional file 1 of Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia

10.6084/m9.figshare.14526563.v1figshare

Additional file 1 of Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia

10.6084/m9.figshare.14526563figshare